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Nano-assemblies of cationic mPEG brush block copolymers with 
gadolinium polyoxotungstate [Gd(W5O18)2]9- form stable, high 
relaxivity MRI contrast agents 
Joanne Ly,a,b Yuhuan Li, a,b Mai N. Vu,a,b Bradford A. Moffatc, Kevin S. Jackd, John F. Quinn,a,b 
Michael R. Whittaker*a,b and Thomas P. Davis*a,b,e 
Polyoxometalates (POMs) incorporating paramagnetic ions, such as gadolinium, show promise as contrast agents for 
application in magnetic resonance imaging (MRI). Specifically, [Gd(W5O18)2]9- (denoted as GdWO) has been reported to have 
a higher relaxivity than commercially available contrast agents, but it’s clinical utility has been limited by the intrinsic 
instability of POMs at physiological pH (7.4). In the current report we present a stability study on neat GdWO and nano-
assemblies of block copolymers with GdWO in the pH range 5.0-7.4 to assess their suitability as MRI contrast agents. Neat 
GdWO only maintained structural stability between pH 5.4 and 6.4, and demonstrated poor MRI contrast at pH 7.4. To 
address this pH instability, GdWO was self-assembled with cationic mPEG brush block copolymers containing 20 or 40 units 
derived from the cationic monomer, 2-dimethylaminoethyl methacrylate (DMAEMA). Nano-assemblies with different 
charge ratios were synthesised and characterised according to their size, stability, contrasting properties and toxicity. The 
longitudinal relaxivity (r1) of the nano-assemblies was found to be dependent on the charge ratio, but not on the length of 
the cationic polymer block. Further investigation of PDMAEMA20 nano-assemblies demonstrated that they were stable over 
the pH range 5.0-7.4, exhibiting a higher r1 than either neat GdWO (2.77 s-1mM-1) or clinical MRI contrast agent Gd-DTPA 
(4.1 s-1mM-1) at pH 7.4. Importantly, the nano-assembly with the lowest charge ratio (0.2), showed the highest r1 (12.1 s-
1mM-1) whilst, stabilising GdWO over the pH range studied, eliciting low toxicity with MDA-MB231 cells.
Introduction 
Biomedical imaging is an important diagnostic tool that can 
provide basic physiological, anatomical and molecular 
information for the detection, diagnosis and monitoring of 
disease states.  Current imaging techniques include magnetic 
resonance imaging (MRI), positron emission tomography (PET), 
single photon emission computed tomography (SPECT), 
computer X-ray tomography (CT), optical imaging and 
ultrasound.1-3 Since its inception in the early 1970s,4, 5 MRI has 
emerged as an invaluable imaging modality with widespread 
clinical application in neurological, musculoskeletal, 
cardiovascular and oncological imaging. From 1995 to 2015, the 
number of MRI scans in the USA alone increased from 1 in 29 
people to 1 in 9 people.6  The popularity of MRI is due to the 
technique’s high spatial resolution, non-invasiveness, and the 
fact that patients are not exposed to ionising radiation during 
the collection of the images.7, 8 To improve contrast, the 
conspicuity of some pathology and improve the specificity of 
the diagnosis, approximately 30% of MRI scans require the use 
of a contrast agent to improve the quality of images.9  
Contrast agents improve the contrast between different tissues 
by providing enhanced proton spin-lattice (T1) and spin-spin (T2) 
relaxation pathways, and hence shortening the relaxation time. 
The effect of the contrast agent on the T1 and T2 relaxation 
pathway is described by the longitudinal relaxivity (r1) and 
transverse relaxivity (r2), with a high relaxivity value indicating a 
larger effect on the relaxation.  The most clinically used contrast 
agents are chelated gadolinium ions (such as Gd-DTPA, Gd-
DOTA, Gd-DO3A, etc.). Gadolinium ions are paramagnetic, and 
enhance contrast because of the strong dipole-dipole 
interactions between their lone electron and the water protons 
in their hydration sphere. To abrogate their associated toxicity, 
gadolinium ions are generally complexed with either a linear or 
cyclic chelating agent.9, 10 Nevertheless, exposure to chelated 
gadolinium ions can still trigger cases of nephrogenic systemic 
fibrosis for MRI patients with compromised kidney function.11  
To further improve contrast and decrease systemic toxicity, 
research groups have focused on incorporating chelated 
gadolinium ions into nanoparticles.  These hybrid nanoparticles, 
including silica nanoparticles,12, 13 gold nanoparticles,14, 15 
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zeolites,16 titanium dioxide,17 polymeric nanospheres,18-20 and 
star polymers,21, 22 show increased relaxivity and lower toxicity 
compared to commercially available products (such as 
Gadovist®).  Recently, there has been an interest in gadolinium-
based nanoparticles as MRI contrast agents. For instance, 
gadolinium oxide (Gd2O3) nanoparticles,23, 24 gadolinium 
phosphate (GdPO4) nanoparticles,25 sodium gadolinium fluoride 
(NaGdF4) nanoparticles,26, 27  gadolinium metal-organic 
framework (MOF) nanoparticles,28-31 and polyoxometalates 
containing gadoliniums ions (Gd-POMs) have each been 
reported to have higher relaxivities, the smaller the 
nanoparticles.  Of particular interest to us have been Gd-POMs 
due to their promising properties for application as a contrast 
agent. 
Polyoxometalates (POMs) are inorganic metal-oxygen clusters 
formed from metal oxide polyhedral units of early transition 
metals, such as tungsten, molybdenum, vanadium, chromium, 
niobium or tantalum.  Since their discovery in 1829 by 
Berzelius,32 a range of POMs with different structure and 
chemical composition have been identified and investigated for 
applications in materials and colloid science, sensors, 
(photo)catalysis, electronics and medicine.33-35 However, there 
are important challenges that remain unanswered in the 
application of POMs in medicine.36 The most important is the 
thermodynamic and kinetic instability of POMs in aqueous 
environments at physiological pH.37 Controlling the pH of the 
working solution is important for the formation of the POM 
framework, and there is a defined pH range in which the POMs 
remain stable. When POMs are exposed to neutral or basic pHs 
(such as physiological pH 7.4), they become unstable and 
degrade,38, 39 and consequently lose their distinctive properties. 
Despite these drawbacks, recent work by Pei and coworkers40-
43 and other groups44, 45 have indicated that some Gd-POMs 
have both attractive imaging properties and desirable 
pharmacokinetic behaviour. For example, [Gd(W5O18)2]9- 
(abbreviated as GdWO) has recently been utilised for MRI. 
GdWO has a reported r1 value of 4.6 s-1mM-1 at 1.5T,46 and 6.89 
s-1mM-1 at 9.39T,40 which is higher than clinically used Gd-DTPA 
(r1 value of 3.3 s-1mM-1 at 1.5T).47 Pei and coworkers data also 
suggests that, of the Gd-POMs examined, GdWO is stable over 
a broad a broader pH range, making it attractive as a clinically 
applied MRI contrast agent.48, 49 However, GdWO was also 
found to have a lower LD50 than Gd-DTPA,10, which the authors 
attributed to high anionic charge and instability of GdWO in 
solution. 
To improve their toxicity profile and imaging properties, the 
incorporation of Gd-POMs into both biological and synthetic 
nanostructures has been proposed. For example, Lixin Wu and 
coworkers formed dendritic assemblies with an amphiphilic 
molecule (alkyl chain and PEG chain with a quaternary 
ammonium head group) and K13[Gd(β2-SiW11O39)2]. These 
researchers determined that the assemblies formed different 
structures depending on the polymer concentration, and 
displayed structure dependent relaxivities.50-52 Chai et al. 
demonstrated that the r1 of GdWO increased by a factor of 3 
when encapsulated with a spermine based cationic 
homopolymer,46 while  Huang et al. introduced GdWO as the 
MRI contrast agent into a cationic polymer-DNA polyionic 
complex for transfection applications.53 More recently, Yong et 
al. synthesised BSA@GdWO hybrid nanoparticles,54 and GdWO 
conjugated chitosan hybrid nanoparticles,55 and investigated 
them as a theranostic nanoprobe; demonstrating the utility of 
GdWO as both an imaging agent for MRI and CT, as well as a 
cancer therapeutic as a radio sensitiser. To the best of our 
knowledge, these are the only cases where Gd-POMs have been 
applied for enhancing MRI contrast to date.  
It is important to note that while these works have examined 
the relaxivities of Gd-POMs, they have neglected to assess the 
effect of pH on the stability and relaxivity of the Gd-POMs 
studied. Indeed, these works did not provide the pH at which 
the relaxivity experiments were performed POMs are well-
known to be unstable at physiological pH (7.4), it is crucial to 
develop strategies for stabilising POMs at physiological relevant 
pH so as to achieve optimum contrast and enable clinical use. 
To address this, we report the analysis of GdWO at different pHs 
to investigate how pH affects the stability and imaging 
properties of GdWO. Further, we stabilised the GdWO by 
addition of a designed block copolymer comprising an 
antifouling ‘stealth’ brush mPEG block and a cationic, POMs 
binding block which leads to the formation of well-defined 
nano-assemblies. These nano-assemblies were characterised 
for their size, shape and surface chemistry and then a 
preliminary MRI investigation was undertaken to acquire the 
relaxivity and stability over time. Finally, the relaxivities of the 
selected nano-assemblies at different physiologically relevant 
pH were evaluated. These results revealed enhanced stability of 
the nano-assemblies at physiological pH, which is reflected by 
sustained high relaxivity across the pH range tested. 
Experimental Section 
Instrumentation 
Attenuated total reflectance Fourier transform infrared 
spectroscopy (ATR-FTIR) spectra were recorded using Shimadzu 
IR Tracer-100 Fourier Transform Infrared spectrometer by 
averaging 512 scans at a resolution of 8 cm-1 in the MIR region 
of 4000-400 cm-1.  
X-ray photoelectron spectroscopy (XPS) was carried out on a 
Kratos AXIS Ultra photoelectron spectrometer with a 
monochromic AI Kα X-ray source (1486.6 eV) at 225 W (15 kv, 
15 mA). The GdWO sample was ground to fine particles and 
mounted onto the grid. First a survey scan of the sample was 
conducted over a binding energy of 1200 – 0 eV with a pass 
energy of 160 eV at 1.0 eV steps and with 100 ms dwell time. 
Then the high resolution scans were taken at pass energy 20 eV, 
with 0.05 eV steps and dwell times of 500 – 2000 ms, depending 
on the species.  
Thermogravimetric analysis (TGA) of the samples was 
performed on a Perkin-Elmer Thermogravimetric Analyzer 
(Pyris 1). Solid samples were heated from 25°C to 700°C at a 
constant temperature increase of 20°C/min using nitrogen as 
the furnace gas with a flow rate of 20 mL/min. The nano-
assembly samples were prepared by dropping the nano-
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assembly solution onto the TGA pans and drying the pans in an 
oven at 80°C.  For the dialysed nano-assembly solution samples, 
dialysis was conducted with a 20 kDa Slide-A-Lyser MINI dialysis 
device against water over 2 days. 
UV-Visible spectrophotometry (UV-Vis) was conducted on a 
Shimadzu UV-3600 UV-VIS-NIR spectrophotometer using quartz 
cuvettes with 10 mm path length.  
Dynamic light scattering (DLS) measurements were carried out 
on a Malvern Zetasizer Nano ZS Series running DTS software 
(laser, 4 mW, λ = 633 nm; angle 173°). Samples were dispersed 
in water and measured at 25°C.  
Transmission electron microscopy (TEM) images were 
recorded without staining using a Tecnai F20 or Tecnai F30 
transmission electron microscope at an accelerating voltage of 
200 kV at ambient temperature. A typical TEM grid preparation 
was conducted as follow: a 2 μL aliquot of a 0.1 wt% solution 
was dropped onto a Formvar-film copper grid (GSCu100F-50, 
Proscitech), after which samples were allowed to dry under air. 
Magnetic resonance imaging (MRI)  scans were taken using a 
7T whole-body MRI scanner (MAGNETON 7T, Siemens 
Healthcare, Erlangen, Germany) using Nova single channel 
transmit with 32 receiver channels with an internal diameter of 
18.5 cm and a 21 cm field of view along the z-direction. For the 
determination of the r1, inversion recovery sequences were 
utilised with different inversion times (65, 200, 400, 500, 1000, 
1500, 3000, and 4000 ms), TR = 5000 ms and TE 2.78 ms. All 
images were acquired with a 1 mm slice thickness, 150 × 112.5 
mm FOV, 512 × 256 matrix size, and 1 average. Signal from each 
well was plotted as function of inversion time and fitted to a 
monoexponential inversion recovery curve to calculate T1. The 
r1 relaxivity for each material was calculated from the linear 
slope of a 1/T1 plotted as a function of calculation. 
Inductively coupled plasma optical emission spectrometry 
(ICP-OES) was used to determine the amount of gadolinium ions 
in the materials using a Perkin-Elmer OPTIMA 7300 
spectrometer. 50 µL of the sample was digested in 200 µL of 
nitric acid (70%) in a water bath at 70°C overnight. The samples 
were then diluted to give a final nitric acid concentration of 
1.4%.  
Proton nuclear magnetic resonance (1H NMR) spectra were 
recorded on an Avance III Nanobay 400 Hz Bruker spectrometer 
coupled to a BACS automatic sample changer. Samples were 
dissolved in deuterated chloroform. Chemical shifts were 
measured in part per million and were referenced to an internal 
standard.  
Gel permeation chromatography (GPC) was used to determine 
the molecular weight distribution of the polymers relative to 
polystyrene samples. Samples were dissolved in N,N-
dimethylacetamide (DMAc, HPLC grade, 0.05% w/v 2,6-dibutyl-
4-methylphenol 0.03% w/v LiBr) to a concentration of 
approximately 1 mg/mL and filtered through a 0.45 µm PTFE 
syringe filter. Analysis was performed on a Shimadzu modular 
system comprising a DGU-20A3R degasser unit, an SIL-20A HT 
autoinjector, a 50 × 7.8 mm 10 µm bead-size guard column 
followed by three 300 × 7.8 mm linear KF-805L columns (bead 
size: 10 µm, pore size maximum: 5000 Å pore size) and a RID-
20A differential refractive-index detector using DMAc as the 
eluent (40 °C, flow rate=1 mL/min). Calibration was achieved 
with commercial narrow-polydispersity polystyrene standards 
ranging from 500 to 2 × 106 g mol-1. 
Materials 
Sodium tungstate dihydrate (Na2WO4·2H2O, >99%), gadolinium 
chloride hexahydrate (GdCl3·6H2O, 99%), acetic acid (>99.7%), 
4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (CPADB), 
poly(ethylene glycol) methyl ether methacrylate (OEGMA, 
Mn=500 g mol-1), 2-(dimethylamino)ethyl methacrylate 
(DMAEMA, 98%) and toluene (anhydrous, 99.8%) were 
purchased from Sigma Aldrich (St. Louis, MO, USA) and used as 
received. 2,2-Azobis(2-methylpropionitrile) (AIBN, 98%) was 
recrystallised from methanol. Dialysis tubing Cellu-Sep 
T1/nominal MWCO:3500 was purchased from Cellu-Sep(Seguin, 
TX, USA). 50× Tris/Acetic Acid/EDTA (TAE) buffer and Certified™ 
Molecular Biology agarose was purchased from Bio-Rad 
(Hercules, CA, USA). 20 kDa Slide-A-Lyser MINI dialysis device 
was purchased from ThermoFisher Scientific (Waltham, MA, 
USA) All other solvents were purchased from Merck Millipore 
(Darmstadt, Germany) and were of analytic grade. Water was 
purified by a Millipore Milli-Q water purification system and had 
a resistivity of 18.2 MΩ⋅cm. MDA-MB231 cells was purchased 
from American Type Culture Collection (Manassas, VA, USA). 
Synthesis of GdWO 
Synthesis of GdWO was based on the published procedures of 
Yamase56 and Peacock57. Briefly, sodium tungstate dihydrate 
(8.30 g, 2.51 × 10-2 mol) was dissolved in 20 mL of MilliQ water.  
The sodium tungstate solution was then adjusted to pH 7.4 
using acetic acid, and then the beaker was covered with 
aluminum foil and then heated to 85°C.  Gadolinium chloride 
hexahydrate (0.929 g, 2.51 × 10-3 mol) was dissolved in 2 mL of 
warm MilliQ water. A syringe pump was used to add the warm 
GdCl3 solution (5 mL syringe, addition rate of 0.5 mL/hour) to 
the stirring and hot Na2WO4 solution. Once all added, the 
solution was taken off the heat and the final pH of the solution 
was 5.4.  The solution was then cooled in an ice bath to form 
GdWO crystals. The GdWO was then dried down by gently 
blowing a stream of compressed air onto the solution.  Finally, 
the GdWO was made in to a stock solution of 2.35 mg/mL. 
Synthesis of cationic mPEG brush block copolymer by reversible 
addition fragmentation chain transfer (RAFT) polymerisation 
Synthesis of mPEG brush macromolecular chain transfer 
(macroRAFT) agent with poly(ethylene glycol) methyl ether 
methacrylate (OEGMA). The polymerisation was carried out 
with the following stoichiometry: [OEGMA]0 /[CPADB]0/[AIBN]0 
= 28/1/0.1. OEGMA (16.00 g, 3.20 × 10-2 mol), CPADB (319 mg, 
1.14 × 10-3 mol), AIBN (18.7 mg, 1.14 × 10-4 mol) and 102.5 mL 
of dry toluene was combined in a glass vial and was purged by 
sparging with N2 for 90 mins. The solution was heated to 70°C 
for 24 hours. The polymer was purified by 5 
precipitation/centrifugation cycles into large excess of 3:2 (v:v) 
mixture of diethyl ether and petroleum benzene (b.p. 40-60°C). 
The polymer was then placed in a vacuum oven overnight to 
remove residual solvent. 
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Synthesis of (POEGMA-b-PDMAEMA) by chain extension of 
macroRAFT agent with DMAEMA. Polymerisation was carried 
out with the following stoichiometry: [DMAEMA]0 
/[macroRAFT]0/[AIBN]0 = 115/1/0.1. DMAEMA (4.00 g, 2.55 × 
10-2 mol), macroRAFT (2.48 g, 2.21 × 10-4 mol), AIBN (3.6 mg, 
2.21 × 10-5 mol) and 13.1 mL of dry toluene was combined in a 
glass vial and purged by sparging with N2 for 60 mins. The 
polymerisation solution was then divided into three glass vials, 
which were fastened with a rubber septa and wire, with the 
approximate volumes of 5 mL, 5 mL and 10 mL. To understand 
the kinetics of the polymerisation, the first vial containing 5 mL 
of polymerisation solution was heated to 70°C for a total of 10 
hours with samples of the polymerisation solution taken at 0, 2, 
4, 6, 8 and 10 hours. The second vial containing 5 mL and the 
third vial containing 10 mL were heated to 70°C for 90 mins and 
4 hours, respectively. The polymers were purified by dialysis 
against acetone over 2 days, and then placed in a vacuum oven 
overnight to remove residual solvent. 
Synthesis of the nano-assemblies 
2 mL of polymer aqueous solution (100 mg/mL) was prepared 
and adjusted to pH 6.0 with HCl. Polymer solution was then 
added dropwise to 5 mL of GdWO aqueous solution (1 mg/mL) 
to give a final pH of approximately 6. Different amounts of 
polymer were added based on the charge ratio equation as 
established by Zhang et al..58 The assemblies had charge ratios 
of 0.2, 0.3, 0.4, 0.5, 0.7 and 0.9. 
pH titration of GdWO 
pH titration of the material was conducted to determine the 
most stable pH range for GdWO. Benchtop pH measurements 
were performed using a Mettler-Toledo SevenCompact pH/Ion 
S220 meter equipped with an InLab Semi-Micro pH electrode. 2 
mL of GdWO aqueous solution was titrated against 0.1 M HCl or 
0.1 M NaOH. 
Preparation of MRI samples 
MRI scans were taken from an aqueous dilution series prepared 
in a Costar 96-well assay block (3959, 1 mL well volume, round 
bottom). To limit artefacts, the backside of the assay block was 
filled with 3% agarose using the following procedure: 300 mL 
TAE buffer ×1 (40 mM tris base, 40 mM acetic acid, and 1 mM 
EDTA) was stirred and 9.0 g agarose was added into the 
solution. The agarose dispersion was heated in a microwave 
until the solution boiled. The solution was decanted into the 
backside of the 96-well assay block. The agarose solution was 
left to cool down in the assay block, until an agarose gel formed.  
Dilution series of GdWOs and Gd-DTPA were prepared in 
aqueous solution (5 dilutions, dilution factor 2, 0.75 mL each, 
highest concentration ∼0.2 mM Gd3+). The exact concentration 
of gadolinium in each dilution series was determined by ICP-
OES. 
Cytotoxicity studies 
MDA-MB231 (breast cancer cell line) was cultured in 96-well 
culture plates with RPMI (Roswell Park Memorial Institute) 1640 
Medium containing FBS (fetal bovine serum) at 37°C under 
humidified 5% CO2 atmosphere. Cell viability was assessed using 
the AlamarBlue assay. Cells were seeded at a density of 5000 
cells per well and incubated for 24 hours for cell attachment. 
The cells were washed twice with PBS (phosphate buffer saline) 
and incubated with different concentration of Gd3+ of the 
material for a further 24 hours at 37°C under 5% CO2 
atmosphere. The wells were then washed twice with PBS and 
replenished with cell culture medium containing 10 µL of 
AlamarBlue, and incubated for another 4 hours. The 
fluorescence was detected by exciting at 540-570 nm and the 
emission read at 580-610 nm using a microplate reader. The 
experiments were conducted in triplicate, and viability was 
calculated as the percent fluorescence relative to the untreated 
control cells. 
Results and Discussion 
Synthesis of GdWO 
[Gd(W5O18)2]9- was synthesised based on methods previously 
described by Yamase et al.56 and Peacock et al.,57 however the 
addition of  the warm gadolinium chloride solution to the 
heated sodium tungstate solution was achieved using a syringe 
pump to provide increased control of the rate of addition.  After 
purification of GdWO, the GdWO crystals were redispersed into 
MilliQ water to give a final concentration of 2.35 mg/mL for 
handling. The synthesis of GdWO was confirmed using ATR-FTIR 
and XPS spectroscopy. Figure 1a shows the infrared spectra of 
GdWO, which was in agreement with previously published 
reports,59 with the identification of a single W=O peak at 
wavenumber 936 cm-1, and a band of W-O-W vibrational peaks 
in the wavenumber region 706 - 833 cm-1. Figure S1 shows the 
XPS high resolution scans which are also in agreement with 
literature, with the identification of the Gd 4d and W 4f and a 
ratio of Gd:W atoms of 1:10 as expected. GdWO was examined 
by thermogravimetric analysis (TGA) generating a TGA curve as 
seen in Figure S2. The TGA curve generated is consistent with 
published works on metal oxide nanoparticles (such as iron 
oxide nanoparticles); with a rapid weight loss of 5.5% at 140°C 
corresponding to the free water molecules and weight loss of 
4% between 140°C – 200°C corresponding to the bound water 
molecules.  
Importantly, POMs are known to be unstable at physiological 
pH in aqueous systems. To investigate this, GdWO was titrated 
against dilute sodium hydroxide (NaOH) and dilute hydrochloric 
acid (HCl) to obtain a titration curve, which to the best of our 
knowledge, has not been previously published for this particular 
POM. The titration curve is shown in Figure 1b, where GdWO in 
aqueous solution has a pH of ca. 6 and is titrated against HCl or 
NaOH. Generally, titration curves of POMs have two distinctive 
end-points, which were detected at pH 5.4 and pH 10.4 for 
GdWO. The first end-point observed at pH 5.4 corresponds to 
the complete neutralisation of the acid protons (H9[Gd(W5O18)2] 
→ [Gd(W5O18)2]9-) and the second end point at pH 10.4 signifies 
the complete degradation of the polyanion ([Gd(W5O18)2]9- → 
WO42-).  Also, intermediate to the two main end-points, another 
end point was also observed at pH 6.5 This end-point is most 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5  
Please do not adjust margins 
Please do not adjust margins 
likely attributed to the degradation of the GdWO sandwich 
framework to its subunit,60 a Lindqvist monovacant derivative 
([Gd(W5O18)2]9- → GdW5O183- + W5O186-). The UV-Vis spectra of 
GdWO at different pH also provides further evidence of the 
breakdown of the sandwich structure (Figure S3). The peak at 
260 nm is monitored on the UV-Vis spectrophotometer as the 
pH of the GdWO solution is increased. There was no change of 
the intensity of the peak when the GdWO solution is adjusted 
from pH 5.9 to pH 6.3, but when the pH was increased to 6.4, 
the intensity of the peak at 260 nm begins to drop. The peak 
intensity continues to decrease until pH 6.6, after which there 
is no change in the peak intensity even up to pH 9.0. The change 
in the peak intensity at pH 6.4 indicates a transformation of the 
GdWO structure, and this also coincides with the titration end 
point involving the degradation of the sandwich structure. 
Correlation of the pH titration and UV-Vis spectroscopy data 
indicates that GdWO has a narrow pH range of optimal stability 
(pH 5.4-6.4), outside of which the GdWO can degrade to its 
building units (at high pH) or possibly form condensed clusters 
(at low pH). 
Subsequently, GdWO solutions at different pHs were 
characterised by dynamic light scattering (DLS) and 
transmission electron microscopy (TEM) to elucidate the 
particle size and shape.  The DLS number average size 
distribution (Figure 1c) indicates that GdWO has a 
hydrodynamic diameter of 25.7 nm at pH 6, which is suggestive 
of GdWO aggregation. This is supported by the TEM images 
showing large groups of small clusters with sizes varying from 
70-170 nm (Figure 1d). Moreover, the hydrodynamic diameter 
of GdWO increased to 105.5 nm when the pH was increased to 
7.0, until eventually only large aggregates above 1000 nm are 
observed at pH 7.4. The change in hydrodynamic diameter is 
attributed to the degradation of GdWO at basic pH, however, it 
is interesting to observe that the hydrodynamic diameter does 
not change at pH 5 (26.5 nm). 
Next, the longitudinal relaxivity (r1) of GdWO at pH 7.4, 6.0 and 
5.0 was determined using a clinical 7T MRI scanner and ICP-OES 
to generate a relaxivity curve shown in Figure 2. At pH 6.0, 
GdWO has a r1 of 8.86 s-1mM-1, which is 2 times higher than the 
clinical contrast agent Gd-DTPA, which has a r1 of 4.43 s-1mM-1 
when measured on the 7T system used here. The relaxivity of 
Gd-DTPA is known to be pH independent at pH>3, therefore the  
relaxivity of Gd-DTPA was not tested at different pH.61 For 
GdWO, the solution was adjusted to pH 5.0, which yielded a 
Figure 1 Characterisation of GdWO: ATR-FTIR spectra (a), titration curve (b), hydrodynamic size distribution at different pH (c) and TEM image (d). 
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slight increase of the r1 from 8.86 to 10.14 s-1mM-1. However, 
when GdWO was adjusted to pH 7.4, the relaxivity was reduced 
significantly to 2.77 s-1mM-1, likely due to the breakdown of the 
sandwich structure of GdWO, and the concomitant loss of 
imaging capabilities.  Only the first three gadolinium 
concentrations (0.125, 0.25, 0.50 mM) were used to calculate 
the r1 of GdWO at pH=7.4 due to the observed precipitation of 
GdWO at higher (0.6409 s-1 at 0.1 mM and 0.6285 s-1 at 0.2 mM). 
The demonstrated instability of GdWO and subsequent loss of 
contrasting ability highlights a significant drawback of GdWO if 
it is to be applied in biomedical imaging at physiological pH. 
Moreover, in certain tissues pH may even be as high as 8.62, 63 
Consequently, neat GdWO is unlikely to be an effective T1 
contrast agent despite displaying promising high relaxivity 
values at pH 6.0. To be suitable for biomedical imaging, GdWO 
needs to be stabilised to protect its structure as well as maintain 
its contrasting properties at physiological pH. As such, we 
explored the stabilisation of GdWO by employing a co-
assembly/coating strategy with a designed cationic mPEG brush 
block copolymer. 
Synthesis of the nano-assemblies 
GdWO is a polyanion, with 9 negative charges, and as such we 
elected to prepare cationic block polymer to enable 
electrostatic binding to GdWO. DMAEMA, a tertiary amine-
containing monomer with a pKa = 8.44, was chosen due to the 
almost complete protonation of the tertiary amines at pH 6. 
However, homopolymers of DMAEMA are slightly cytotoxic due 
to its cationic nature, and for that reason, a PEG brush block was 
incorporated into the polymer design.64 Furthermore, literature 
has also shown that PEGylation of nanoparticles can improve 
their biodistribution (through mechanisms such as decreasing 
uptake by the reticuloendothelial system, decreasing 
degradation via metabolic enzymes, and prolonging blood 
circulation etc.), leading to the enhancement of the therapeutic 
effect and/or imaging quality.65-67 To this end, RAFT 
polymerisation was employed to synthesise a starting PEG 
brush block, followed by chain extension with DMAEMA to form 
the PDMAEMA domain (Scheme 1). 
First, the mPEG brush macromolecular chain transfer 
(“macroRAFT”) agent was synthesised with 22 OEGMA units, as 
determined by 1H NMR. The macroRAFT agent was then chain 
extended with DMAEMA resulting in the POEGMA-b-PDMAEMA 
stabilising agents. Different lengths of the PDMAEMA domain 
were achieved by varying the polymerisation time: 1.5 hrs was 
used to provide 21 units of DMAEMA (denoted as PDMAEMA20) 
while a polymerisation time of 4 hrs was used for 46 units of 
DMAEMA (denoted as PDMAEMA40). The polymers were 
characterised by GPC to determine the molecular weight 
distribution and polydispersity, and 1H NMR to confirm the 
composition (Table 1 and Figure S4). 
Table 1 Characterisation of RAFT polymers 
a Polymerisation [total monomers]=[M]0; [RAFT agent]=[CTA]0. b % Monomer conversion determined using 1H NMR spectroscopy. c Theoretical number-average molecular 
weight: Mn(theory) = ([M]0/[CTA]0) × conversion × (MWmonomer) + (MWRAFT agent). d 1H NMR determined molecular weight by integration of 2 protons on the benzyl group 
(RAFT agent) and the protons of the monomers (i4.1, i3.4). The following equation was used for POEGMA Mn(NMR) = (i4.1/i7.9) ×  500. The following equation was used for 
POEGMA-b-PDMAEMA Mn(NMR) = 11200 + 157.21[(3i4.1 – 2i3.4)/3i7.9].  e Determined by GPC analysis in DMAc using polystyrene standards. f Dispersity determined by 
GPC analysis in DMAc. 










POEGMA 28 68.6 9880 11200 11700 1.10 
POEGMA-b-PDMAEMA20 136 18.5 15150 14500 12300 1.11 
POEGMA-b-PDMAEMA40 136 34.6 18600 18400 14400 1.12 
Figure 2 Relaxivity measurement of GdWO at pH 5.0, 6.0 and 7.4 on a 7T MRI scanner. 
Scheme 1 RAFT polymerisation of the cationic mPEG brush block copolymer – POEGMA-b-PDMAEMA. 
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After synthesis, extensive purification by dialysis in acetone and 
full characterisation, the polymers were made up into aqueous 
solution at 100 mg/mL and adjusted to pH 6 with hydrochloric 
acid to provide the protonated form of the tertiary amine 
moieties (Scheme 2). The protonation of the tertiary amine also 
prevented the self-assembly of the polymers in aqueous 
solution, which was confirmed on the DLS (Figure S5). The 
polymer solution was then added dropwise to the stirring 
solution of GdWO, affording the nano-assemblies. Different 
amount of polymer were added to the solution based on Zhang 
et al.’s charge ratio equation: 𝛾 =
𝐶+
𝐶++𝐶−
 where C+ is the moles 
of positive charge, and C- is the moles of negative charge.58 Six 
charge ratios were chosen for assembly of the polymers with 
GdWO: 0.2, 0.3, 0.4, 0.5, 0.7 and 0.9.  The nano-assemblies are 
denoted as [charge ratio]P[units of DMAEMA in polymer]@GdWO; for 
example, the nano-assembly with PDMAEMA20 and a charge 
ratio of 0.2 is denoted as 0.2P20@GdWO. Theoretically, there are 
multiple GdWO nanocrystals per polymer chain for the nano-
assemblies with charge ratio 0.2-0.5. While, 0.7P20@GdWO and 
0.9P20@GdWO have 1 and 4 polymer chains per GdWO, 
respectively. 0.7P40@GdWO and 0.9P40@GdWO have 0.5 and 2 
polymer chains per GdWO, respectively. TGA analysis of the 
nano-assemblies both before and after exhaustive purification 
by dialysis revealed the participation of all polymer chains in the 
formation of the nano-assemblies. Specifically, as seen in Figure 
S6, there is no difference in the TGA profiles of 0.2P20@GdWO 
pre- and post-dialysis to remove free polymer chains.  
DLS provided further evidence of the cationic polymer 
interacting with the GdWO, and forming assemblies as shown 
in Figure 3a for PDMAEMA20 and Figure S7a for PDMAEMA40. 
GdWO initially has a hydrodynamic diameter of ca. 26 nm, but 
when either PDMAEMA20 or PDMAEMA40 is introduced to the 
GdWO solution, the hydrodynamic diameter decreases to 
between 11-13.5 nm. This suggests that the polymer disrupts 
the aggregation and stabilises the GdWO. However at higher 
polymer/GdWO ratio of 0.9P20@GdWO and 0.9P40@GdWO, the 
formation of larger more complex assemblies was observed. 
TEM images of the 0.2P20@GdWO nano-assemblies suggest the 
formation of spherical assemblies with sizes ranging from 4.7-
22.4 nm (Figure 3b). TEM images of the other nano-assemblies 
can be seen in Figure S8. Figure 3c shows the ζ-potential of the 
P20@GdWO nano-assemblies compared to the neat GdWO (-
25.7 mV) and PDMAEMA20 (+20.4 mV) revealing the expected 
charge inversion. 
Preliminary investigation of the r1 of the assemblies at pH 6 
were conducted on a clinical 7T MRI machine to determine if 
the charge ratio and/or the length of the tertiary amine block 
polymer influences relaxivity. The r1 of the P20@GdWO and 
P40@GdWO nano-assemblies were calculated and are given in 
Figure 4. All of the nano-assemblies have r1 values higher than 
Gd-DTPA, however when compared to GdWO alone, only the 
nano-assemblies with charge ratio of 0.2 have a slightly higher 
r1 (9.58 s-1mM-1 and 10.02 s-1mM-1 for 0.2P20@GdWO and 
0.2P40@GdWO respectively). As the charge ratio of the nano-
assemblies was increased to 0.3, 0.4 and 0.5, there is an 
observed decrease in the r1. Above a charge ratio of 0.5, the r1 
of the nano-assemblies was found to increase. When comparing 
PDMAEMA20 to PDMAEMA40, there is no significant 
improvement of the r1 between the nano-assemblies comprised 
of these two polymers. The P20@GdWO series of nano-
assemblies was therefore selected for further studies. 
Stability of the nano-assemblies  
The stability of the P20@GdWO series of nano-assemblies was 
assessed by monitoring the hydrodynamic size on DLS and 
Scheme 2 Schematic illustration representing GdWO interacting with cationic mPEG 
brush block copolymer to form the nano-assemblies.
Figure 3 DLS determined number average particle size of P20@GdWO nano-assemblies at week 1 and week 7 (a) followed by a TEM image of 0.2P20@GdWO (b). DLS 
determined ζ-potential of the P20@GdWO nano-assemblies (c). 
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measuring the r1 over the course of 7-10 weeks. Both 
techniques indicated that most of the P20@GdWO nano-
assemblies demonstrated stable aize and stability for at least 2 
months. Figure 3a shows the hydrodynamic diameter of the 
assemblies at week 1, then at week 7. For the assemblies, 
except for 0.9P20@GdWO, there is little change in the 
hydrodynamic diameter, with measurements in the range of 
11.7-12.75 nm (corresponding to less than 12% change in size.) 
0.9P20@GdWO had a 49.0% increase in hydrodynamic size; from 
74.24 to 110.6 nm indicating some instability at this higher 
charge ratio. 
The P20@GdWO nano-assembly dilution samples from the 
preliminary MRI study were stored at room temperature and in 
the dark after their initial MRI scan. The samples were rerun on 
the MRI machine ten weeks later, and the change in r1 is given 
in Table 2. 0.2P20@GdWO - 0.7P20@GdWO showed little change 
in signal, with variation in relaxivity ranging from -3.5 to 2.3%. 
Once again, the exception is 0.9P20@GdWO, as the r1 decreased 
by 13.8% reflecting the fact that 0.9P20@GdWO is unstable. 
Table 2 Relaxivity measurement of the P20@GdWO nano-assemblies at week 1 and 10 
Nano-assembly 
r1 at pH 6 
Week 1 
r1 at pH 6 
Week 10 
change in r1 
0.2P20@GdWO 9.36 9.58 2.3% 
0.3P20@GdWO 8.20 8.28 1.0% 
0.4P20@GdWO 6.56 6.59 0.4% 
0.5P20@GdWO 4.98 5.03 0.9% 
0.7P20@GdWO 6.73 6.49 -3.5% 
0.9P20@GdWO 7.52 6.48 -13.8% 
 
Relaxivity study of the nano-assemblies at different pH 
The nano-assemblies were assessed at pH 7.4, 6.0 and 5.0 on 
the 7T MRI scanner to investigate the ability of the block 
copolymer to stabilise the GdWO, and maintain the r1 signal at 
physiologically relevant pHs. As demonstrated earlier, GdWO 
loses its functionality as a contrast agent at physiological pH and 
as such is unsuitable for clinical application. In contrast, the 
P20@GdWO nano-assemblies were found to be very stable in 
the pH range 5.0-7.4, with sustained high relaxivity as evident in 
Figure 5 and 6. 
Figure 5 presents the MRI phantom image as a visual indicator 
of the effectiveness of the nano-assemblies as contrast agents. 
Generally for T1-weighted images, the brighter the image at 
lower concentration, the more effective the contrast agent.  
When comparing the brightness of GdWO at pH 7.4 and pH 6.0, 
it is evident that GdWO loses it’s contrasting properties 
significantly at pH 7.4. The MRI phantoms of the 0.2P20@GdWO 
and 0.3P20@GdWO are also compared; these were chosen as the 
preliminary MRI relaxivity data indicated that they had the 
highest r1 value. At pH 7.4, the phantom images of 
0.2P20@GdWO and 0.3P20@GdWO are much brighter than neat 
GdWO, suggesting that the polymer is not only protecting 
GdWO, but also maintaining its contrasting properties against 
changes in pH. The phantom images were then used to 
determine r1 values for all the nano-assemblies and GdWO at 
different pHs, with the values given in Figure 6. GdWO itself 
performed better at pH 5.0 and pH 6.0 than most of the 
P20@GdWO nano-assemblies, with the exception of 
0.2P20@GdWO. However, at pH 7.4, the P20@GdWO nano-
assemblies had an r1 value 2-4 times higher than neat GdWO. 
Figure 5 T1-weighted MRI phantom images of Gd-DTPA, GdWO and the selected 
nano-assemblies 0.2P20@GdWO and 0.3P20@GdWO at pH 7.4 and pH 6.0. Gd-DTPA is 
not affected by pH, thus, there is only a phantom image at pH 7.4.
Figure 4 Relaxivity measurements of the P20@GdWO and P40@GdWO nano-
assemblies at different charge ratios. The dotted line represents the r1 of Gd-DTPA.
Figure 6 Relaxivity study of the P20@GdWO nano-assemblies com-pared to GdWO 
at pH 5.0, 6.0 and 7.4. Line is not fitted data, only guidance for the eye.
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Focusing at pH 7.4, the P20@GdWO nano-assemblies show 
evidence of the charge ratio influencing the r1. At low charge 
ratio (ie. multiple GdWO per chain), there is enhancement of 
the r1 of the nano-assemblies, as observed for 0.2P20@GdWO, 
0.3P20@GdWO and 0.4P20@GdWO.  Then, for 0.5P20@GdWO, 
0.7P20@GdWO and 0.9P20@GdWO, there is an inversion of the 
trend – r1 decreases as the charge ratio increases. This suggests 
that the polymer concentration, which dictates the formation 
of the nano-assemblies, affects the relaxivity of the nano-
assemblies. The formation of the nano-assemblies may 
influence the interaction of the embedded GdWO with the 
surrounding water molecules (one of the key mechanism for 
gadolinium ions as a contrast agents), resulting in either an 
enhancement or reduction of the r1. Once again, 0.9P20@GdWO 
is an exception demonstrating a linear relationship between r1 
and pH; a r1 of 8.50 s-1mM-1 at pH 5.0, 7.53 s-1mM-1 at pH 6.0 
and then 6.15 s-1mM-1 at pH 7.4.  Altogether, most of the 
P20@GdWO nano-assemblies are stable at physiologically 
relevant pH and have a higher r1 value than Gd-DTPA across all 
pHs studies, in stark contrast to neat GdWO.  
Cytotoxicity studies 
Finally the cytotoxicity of GdWO, polymer and the nano-
assemblies were evaluated using the AlamarBlue assay on 
MDA-MB231 (breast cancer cell line) cells.  As shown in Figure 
7, the cells tolerated the neat GdWO and Gd-DTPA with a slight 
decrease of the cell viability at the highest concentration 
investigated. The cells were treated with the P20@GdWO nano-
assemblies based on the concentration of the Gd3+; with most 
nano-assemblies being well tolerated by the cells. The toxic 
nature of 0.9P20@GdWO is likely due to the high cationic polymer 
content, and as such, 0.9P20@GdWO is unlikely to be suitable as 
a nano-assembly for MRI imaging.  The low charge ratio nano-
assemblies, 0.2P20@GdWO and 0.3P20@GdWO, were most 
biocompatible showing cell viability just under 80% at the 
highest tested gadolinium concentration. As such, the observed 
biocompatibility of 0.2P20@GdWO and 0.3P20@GdWO suggests 
that they are potential candidates for application as contrast 
agents. 
Conclusions 
In conclusion, we have demonstrated that GdWO exhibits the 
properties of an effective contrast agent at pHs below 6.4. 
However, above this pH, the structure of GdWO becomes 
compromised, resulting in insufficient shortening of the 
longitudinal relaxation time and essentially rendering GdWO 
useless as a contrast agent. To ameliorate this deficiency, 
GdWO was assembled with mPEG brush block copolymer with 
a cationic segment at different charge ratios to prepare a series 
of hybrid GdWO nano-assemblies. We have demonstrated that 
the observed r1 of the prepared nano-assemblies was charge 
ratio dependent, but that the length of the cationic polymer 
block does not affect r1 within the range of block lengths tested. 
Representative P20@GdWO nano-assemblies were examined 
for stability, relaxivity and cytotoxicity studies. With the 
exception of 0.9P20@GdWO, the P20@GdWO nano-assemblies 
showed good stability, with no major change in r1 or size over 
10 weeks and good r1 at physiologically relevant pH.  The best 
performing nano-assembly in terms of stability, high relaxivity 
Figure 7 Cytotoxicity study of GdWO, Gd-DTPA and the nano-assemblies with AlamarBlue assay
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and low cytotoxicity was 0.2P20@GdWO, making it a suitable and 
promising nano-assembly for further in vivo studies.  This 
research demonstrates the important impact of pH on POMs for 
MRI applications, and the potential for using well-defined 
polymeric stabilisers to enable use of POMs at physiologically 
relevant pHs. 
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